News
By Twesha Dikshit (Reuters) -European stocks edged higher on Friday, led by upbeat corporate earnings and a jump in Novo ...
Novo Nordisk shares jumped more than 5% on Friday, extending Thursday’s rally, after Eli Lilly’s obesity pill data fell short of market expectations.
Novo Nordisk continues to deliver double-digit revenue and profit growth, driven by both its diabetes and obesity drug ...
Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...
The investment conglomerate reported a higher-than-expected profit, aided by a recovery in its te ...
Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a ...
European shares edged higher and were on track for their biggest weekly gain in 12 as investors assessed U.S. President ...
Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback